15 Results

Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience.

The study aimed to describe real-life experience in advanced HCC treatment with SOR at a university hospital in Brazil and to estimate the number of patients with indication of second-line therapy.

Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.

The hepatocellular carcinoma (HCC) treatment landscape changed a decade ago, with sorafenib demonstrating survival benefit in the first-line setting and becoming the first systemic therapy to be approved for HCC.

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications.

Over the past ten years, sorafenib, a multikinase inhibitor, has been the only systemic agent approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.

Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of hepatocellular carcinoma and the development of resistance...

The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review.

Background: The ideal management for patients with intermediate and advanced stage hepatocellular carcinoma (HCC) is controversial. The main purpose of this systematic review is to examine the role of liver resection...

Interaction of margin status and tumour burden determines survival after resection of colorectal liver metastases: A retrospective cohort study.

Purpose: We sought to determine the impact of surgical margin status on overall survival (OS) and recurrence pattern stratified by tumor burden.

CEACAM1 is associated with recurrence after hepatectomy for colorectal liver metastasis.

Background: Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is re-expressed at the invasion front of colorectal cancer. CEACAM1 expression at metastatic sites remains to be investigated.

Parenchymal sparing surgery for colorectal liver metastases: The need for a common definition.

Background: The definition of parenchymal sparing surgery (PSS) for colorectal liver metastases (CRLM) diverges requiring a clarification of the concept.

Long-term outcome and quality of life after initial and repeat resection of colorectal liver metastasis: A retrospective analysis.

Background: Repeat hepatectomy is a widely accepted treatment for patients with recurrent colorectal liver metastasis (CRLM). The aim of this study was to compare initial and repeat hepatic resection concerning overall survival...

Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria.

Background: Orthotopic liver transplantation is a curative treatment for hepatocellular carcinoma within Milan criteria, but these criteria preclude many patients from transplant candidacy.

Load more